Skip to content
Thursday, 12 November 2026Malta edition Enquire Malta-24 Briefing @CDNewsDispatch
Malta's world news feed Local perspective with global outlook
CDE.NEWS The Dispatch
Enquire
LATEST
European Parliament elects new vice-president, backs proxy voting around childbirth Bomb alert temporarily halts trains at Calais station, causing Eurostar delays Cyprus Commissions Study to Attract Maritime Tech and New Shipping Firms Russian diplomat says Moscow could conclude non-aggression pacts with NATO member states European gaming firms say new EU consumer rules will ‘cripple’ the industry
Switzerland

Swissmedic approves Roche’s Ronapreve to treat COVID-19 patients

cde.news desk · 1 min read
Xinf
The logo of Swiss pharmaceutical company Roche at the headquarters in Basle, Switzerland . EPA-EFE/STEFFEN SCHMIDT

ZURICH, Dec 27 (Reuters) – Swiss drugs regulator Swissmedic said on Monday it approved Ronapreve, an antibody treatment jointly developed by Roche and Regeneron, to treat COVID-19 patients.

“In this procedure, no data on efficacy against the Omicron variant were submitted,” Swissmedic said in a statement.

The antibody treatment was already authorised for prescription in Switzerland under COVID-19 Ordinance 3 since April 15, Swissmedic said.

(Reporting by Silke Koltrowitz, Editing by Miranda Murray)

Photo – The logo of Swiss pharmaceutical company Roche at the headquarters in Basle, Switzerland . EPA-EFE/STEFFEN SCHMIDT

Filed under CoronavirusSwitzerland
Topics RocheSwitzerland

More from Switzerland

More →
Switzerland

Swiss voters reject tighter neutrality rules that would have curbed NATO cooperation

 Switzerland

Switzerland votes on proposal to enshrine stricter neutrality in constitution

 Switzerland

UN says global warming likely to exceed 1.5C within a few years